TD Cowen raised the firm’s price target on Roche (RHHBY) to $67 from $60 and keeps a Hold rating on the shares. The firm updated its model following results of the Phase III FENtrepid trial of fenebrutinib versus Ocrevus in PPMS show solid efficacy with manageable safety, but role in treatment paradigm keyed to FDA monitoring requirements.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- VIG vs. VYM vs. VYMI: Which Is Vanguard’s Best Dividend ETF for Reliable Passive Income?
- Roche’s Genentech announces fenebrutinib met its primary endpoint
- Trump Trade: Argentina says U.S. to cut hundreds of tariffs
- TrumpRx website using technology from GoodRx, STAT says
- Roche price target raised to CHF 295 from CHF 290 at Morgan Stanley